Background: Anti-programmed cell death protein 1 (PD-1) has been successfully 
used in carcinomas treatment. However, it causes significant adverse effects 
(AEs), including cutaneous reactions, particularly the life-threatening severe 
bullous skin reactions (SBSR) and toxic epidermal necrolysis (TEN). Case 
summary: Herein, we described for the first time a case report of SBSR induced 
by anti-PD-1 therapy in a cervical cancer patient. In addition, we revised 
existing literature on anti-PD-1 induced cutaneous reactions. We reported a 
cervical cancer patient who was treated with four successive cycles of 
Sintilimab and Toripalimab injections and developed systemic rashes, bullae, and 
epidermal desquamation, which worsened and led to infection, eventually causing 
death after being unresponsive to aggressive treatments. Conclusion: Anti-PD-1 
antibodies commonly cause skin toxicity effects, some of which may be deadly. 
Therefore, healthcare providers should observe early symptoms and administer 
proper treatment to prevent aggravation of symptoms.